Emergent BioSolutions Inc. (NYSE:EBS) experienced a 4.5% uptick in after-hours trading on Wednesday after announcing that the Administration for Strategic Preparedness and Response (ASPR) had exercised a contract option worth $54 million. The award covers additional doses of CNJ-016, identified as Vaccinia Immune Globulin Intravenous (Human), which is used to treat complications arising from smallpox vaccination.
The $54 million action is an option exercise under an existing 10-year agreement between ASPR and Emergent. Company materials describe CNJ-016 as FDA-approved for treatment of complications stemming from smallpox vaccination.
In a separate development, Emergent disclosed that it received $6.6 million in new orders from an unnamed international government partner for ACAM2000, a live smallpox vaccine that sits within the companys medical countermeasures portfolio. The company stated these orders are intended to support the partners smallpox biodefense strategy.
Both announcements come after Emergent finalized multi-year agreements with the Government of Canada valued up to $140 million CAD. According to the company, more than $35 million CAD in orders from those Canadian agreements will be received during 2026, providing a near-term schedule for a portion of that contracted value.
Context and product descriptions
CNJ-016 is described by the company as an FDA-approved treatment for complications resulting from smallpox vaccination. ACAM2000, by contrast, is noted as a live smallpox vaccine that is used for biodefense purposes. Both products are part of Emergents medical countermeasures offerings aimed at preparedness against biologic threats.
Market reaction
The disclosure of the ASPR option exercise and the international ACAM2000 order corresponded with a rise in Emergents stock in after-hours trading, with the shares up 4.5% on the session following the announcements.
What this means for stakeholders
For investors and observers of government biodefense procurement, the awards reinforce Emergents role as a supplier of specialized smallpox-related countermeasures. The Canadian agreements, together with the ASPR option and the international order, represent multiple channels through which Emergent expects to deliver product and recognize associated revenue under existing contracts.
While the company highlighted the dollar values tied to these actions, the announcements did not include additional operational details such as production timelines beyond the 2026 note for a portion of Canadian orders, nor did they identify the international government customer for the ACAM2000 orders.